Coinciding with the World ADC San Diego 2022 conference, Biocytogen and SABPA （Sino-American Biotechnology and Pharmaceutical Professional Association） will jointly organize the Next-Gen Antibody and ADC Symposium on September 6 at Jones Day, San Diego. This Symposium is also called the 27th SABPA Entrepreneur Symposium.

Dr. Frank An, Biocytogen’s Senior Director of Antibody Therapeutics, will introduce the latest progress of the company’s antibody development platform and ADC assets through an oral presentation. The title of the presentation is “Discovery of bispecific ADCs with fully human common light chain antibodies on the RenLiteTM platform”.

In addition, many experts in ADC fields will be invited to talk about the ADC drug development trend. Confirmed panelists includes Hui Li Ph.D （President & CEO, Adcentrx Therapeurics Inc）；Frank An Ph.D （Biocytogen Pharmaceuticals）； Shawn Zhang Ph.D （EVP R&D Operations，General Manager of Ambrx China）； Hanhua Huang Ph.D (VP of Biology, Avidity Biosciences); Fu Li Ph.D (Director of Biology, Mersana Therapeutics) and Xiaona Jing, Ph.D (VP of Global Product Development at Multitude Therapeutics). Biocytogen’s new drug R&D team and business development team will attend the meeting.

Registration Link (FREE)：

https://www.eventbrite.com/e/the-27th-sabpa-entrepreneur-symposium-tickets-406201237837

Only the first 80 registrants will be confirmed for in-person attendance dut to venue capacity, therefore early registration is encouraged.

Take this opportunity to thank SABPA Entrepreneur Committee Members.